| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | May 03, 2024 | Option Exercise | $2.48 | 1,000 | 2,480 | 1,000 | May 07, 2024, 06:58 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | May 03, 2024 | Sale | $22.50 | 1,000 | 22,500 | 0 | May 07, 2024, 06:58 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Apr 29, 2024 | Option Exercise | $2.48 | 3,250 | 8,060 | 3,250 | May 01, 2024, 07:02 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Apr 29, 2024 | Sale | $16.97 | 3,250 | 55,165 | 0 | May 01, 2024, 07:02 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Apr 11, 2024 | Option Exercise | $2.48 | 14,000 | 34,720 | 14,000 | Apr 15, 2024, 07:04 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Apr 11, 2024 | Sale | $24.72 | 14,000 | 346,149 | 10,223 | Apr 15, 2024, 07:04 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Mar 27, 2024 | Option Exercise | $2.48 | 3,250 | 8,060 | 3,250 | Mar 29, 2024, 05:59 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Mar 27, 2024 | Sale | $18.25 | 3,250 | 59,302 | 182 | Mar 29, 2024, 05:59 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Feb 27, 2024 | Sale | $16.97 | 3,250 | 55,163 | 0 | Feb 29, 2024, 05:27 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Feb 27, 2024 | Option Exercise | $2.48 | 3,250 | 8,060 | 3,250 | Feb 29, 2024, 05:27 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Jan 29, 2024 | Option Exercise | $2.48 | 3,250 | 8,060 | 3,250 | Jan 31, 2024, 09:20 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Jan 29, 2024 | Sale | $15.81 | 3,250 | 51,388 | 0 | Jan 31, 2024, 09:20 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Dec 29, 2023 | Sale | $15.00 | 20 | 300 | 0 | Jan 02, 2024, 07:59 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Jan 02, 2024 | Option Exercise | $2.48 | 9,383 | 23,270 | 9,383 | Jan 02, 2024, 07:59 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Jan 02, 2024 | Sale | $15.01 | 9,383 | 140,839 | 0 | Jan 02, 2024, 07:59 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Dec 28, 2023 | Option Exercise | $2.48 | 2,467 | 6,118 | 2,467 | Jan 02, 2024, 07:59 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Dec 28, 2023 | Sale | $15.07 | 2,467 | 37,188 | 0 | Jan 02, 2024, 07:59 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Dec 29, 2023 | Option Exercise | $2.48 | 20 | 50 | 20 | Jan 02, 2024, 07:59 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Dec 26, 2023 | Option Exercise | $2.48 | 100 | 248 | 100 | Dec 27, 2023, 05:26 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Dec 26, 2023 | Sale | $15.00 | 100 | 1,500 | 0 | Dec 27, 2023, 05:26 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Dec 22, 2023 | Option Exercise | $2.48 | 1,030 | 2,554 | 1,030 | Dec 27, 2023, 05:26 PM | |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | Dec 22, 2023 | Sale | $15.07 | 1,030 | 15,525 | 0 | Dec 27, 2023, 05:26 PM |
Menu